title: [Potential of liposomes for the intravitreal injection of therapeutic molecules].
abstract: Intravitreal administration has been widely used since 20 years and has been shown to improve the treatment of diseases of the posterior segment of the eye with infectious origin or in edematous maculopathies. This route of administration allows to achieve high concentration of drug in the vitreous and avoids the problems resulting from systemic administration. However, two basic problems limit the use of intravitreal therapy. Many drugs are rapidly cleared from the vitreous humor; therefore, to reach and to maintain effective therapy repeated injections are necessary. Repeated intravitreal injections increase the risk of endophthalmitis, damage to lens, retinal detachment. Moreover, some drugs provoke a local toxicity at their effective dose inducing side-effects and possible retinal lesions. In this context, the development and the use of new drug delivery systems for intravitreal administration are necessary to treat chronic ocular diseases. Among them, particulate systems such as liposomes have been widely studied. Liposomes are easily injectable and permit to reduce the toxicity and to increase the residence time of several drugs in the eye. They are also able to protect in vivo poorly-stable molecules from degradation such as peptides and nucleic acids. Some promising results have been obtained for the treatment of retinitis induced by cytomegalovirus in human and more recently for the treatment of uveitis in animal. Finally, the fate of liposomes in ocular tissues and fluids after their injection into the vitreous and their elimination routes begin to be more known.
authors: UMR CNRS « physico-chimie-pharmacotechnie-biopharmacie », faculté de pharmacie, université Paris-Sud, Châtenay-Malabry, France. amelie.bochot@u-psud.fr
authors: A
authors: A
authors: Bochot
authors: L
authors: L
authors: Lajavardi
authors: S
authors: S
authors: Camelo
authors: J-L
authors: JL
authors: Bourges
authors: F
authors: F
authors: Behar-Cohen
authors: Y
authors: Y
authors: de Kozak
authors: E
authors: E
authors: Fattal
mesh_terms: D004337:Drug Carriers / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D064420:Drug-Related Side Effects and Adverse Reactions; D005123:Eye / Q000378:metabolism; D005128:Eye Diseases / Q000188:drug therapy*; D006801:Humans; D058449:Intravitreal Injections; D008081:Liposomes / Q000493:pharmacokinetics; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D014822:Vitreous Body / Q000502:physiology*
chemical_list: D004337:Drug Carriers; D008081:Liposomes; D004364:Pharmaceutical Preparations